Workman P
Cancer Chemother Pharmacol. 1980; 5(1):27-37.
PMID: 7460192
DOI: 10.1007/BF00578559.
Tannock I
Br J Cancer. 1980; 42(6):861-70.
PMID: 7459220
PMC: 2010590.
DOI: 10.1038/bjc.1980.334.
Honess D, Workman P, Morgan J, Bleehen N
Br J Cancer. 1980; 41(4):529-40.
PMID: 7387851
PMC: 2010260.
DOI: 10.1038/bjc.1980.95.
Workman P, Bleehen N, Wiltshire C
Br J Cancer. 1980; 41(2):302-4.
PMID: 7370170
PMC: 2010192.
DOI: 10.1038/bjc.1980.43.
White R, Workman P
Br J Cancer. 1980; 41(2):268-76.
PMID: 7370166
PMC: 2010189.
DOI: 10.1038/bjc.1980.39.
Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.
Moore J, Paterson I, Newman H, Venables S
Br J Cancer. 1981; 44(4):592-6.
PMID: 7295516
PMC: 2010798.
DOI: 10.1038/bjc.1981.232.
Structure-pharmacokinetic relationships for misonidazole analogues in mice.
Workman P, Brown J
Cancer Chemother Pharmacol. 1981; 6(1):39-49.
PMID: 7273265
DOI: 10.1007/BF00253009.
Absorption and distribution of vaginally administered misonidazole.
Ash D, Bugden R, Calvert R
Cancer Chemother Pharmacol. 1982; 9(2):118-9.
PMID: 7172406
DOI: 10.1007/BF00265391.
Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
Brown J, Hirst D
Br J Cancer. 1982; 45(5):700-8.
PMID: 7082556
PMC: 2011020.
DOI: 10.1038/bjc.1982.111.
The penetration of misonidazole into a mature structural cartilage.
Langler A, Bugden R, Gibson P
Br J Cancer. 1982; 45(2):282-5.
PMID: 7059476
PMC: 2010886.
DOI: 10.1038/bjc.1982.44.
A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma.
Bleehen N, Wiltshire C, Plowman P, Watson J, Gleave J, Holmes A
Br J Cancer. 1981; 43(4):436-42.
PMID: 7016157
PMC: 2010639.
DOI: 10.1038/bjc.1981.64.
Chemosensitization by lipophilic nitroimidazoles.
Twentyman P, Workman P
Br J Cancer. 1983; 48(1):17-26.
PMID: 6871076
PMC: 2011422.
DOI: 10.1038/bjc.1983.152.
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.
Lee F, Workman P
Br J Cancer. 1983; 47(5):659-69.
PMID: 6849803
PMC: 2011404.
DOI: 10.1038/bjc.1983.104.
An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole.
Twentyman P, Workman P
Br J Cancer. 1983; 47(2):187-94.
PMID: 6824566
PMC: 2011280.
DOI: 10.1038/bjc.1983.26.
The effect of phenytoin, phenobarbitone, dexamethasone and flurbiprofen on misonidazole neurotoxicity in mice.
SHELDON P, Clarke C, DAWSON K
Br J Cancer. 1984; 49(2):207-13.
PMID: 6696821
PMC: 1976702.
DOI: 10.1038/bjc.1984.33.
The role of dexamethasone in the modification of misonidazole pharmacokinetics.
Jones D, Bleehen N, Workman P, Walton M
Br J Cancer. 1983; 48(4):553-7.
PMID: 6626454
PMC: 2011507.
DOI: 10.1038/bjc.1983.228.
Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
Horsman M, Evans J, Brown J
Br J Cancer. 1984; 50(3):305-16.
PMID: 6466544
PMC: 1976784.
DOI: 10.1038/bjc.1984.177.
Preclinical pharmacokinetics of benznidazole.
Workman P, White R, Walton M, OWEN L, Twentyman P
Br J Cancer. 1984; 50(3):291-303.
PMID: 6466543
PMC: 1976805.
DOI: 10.1038/bjc.1984.176.
Radiation and nitroimidazoles in supratentorial high grade gliomas: a second clinical trial.
Urtasun R, Feldstein M, Partington J, Tanasichuk H, Miller J, Russell D
Br J Cancer. 1982; 46(1):101-8.
PMID: 6285947
PMC: 2011055.
DOI: 10.1038/bjc.1982.171.
A phase I study of misonidazole and pelvic irradiation in patients with carcinoma of cervix.
Thomas G, Rauth A, Black B, Cummings B, Sorenti V, Bush R
Br J Cancer. 1982; 45(6):860-8.
PMID: 6284190
PMC: 2011033.
DOI: 10.1038/bjc.1982.138.
